This study aims at assessing the reduction of consumption of corticosteroids (same mid-potent corticosteroids for all patients) afforded by the use of a specific emollient in comparison to the usual one in subjects suffering from atopic dermatitis.
The study is conducted in compliance, as closely as possible, with the current version of the world medical association declaration of Helsinki, local regulations based on International Council on Harmonisation (ICH) guidelines for Good Clinical Practice. The primary objective of this study is to compare the tested emollient and the usual emollient through the weight of used dermocorticosteroid. The weight of used dermocorticosteroid is compared at the end of the study by a Student t-test (or a non parametric Wilcoxon test depending on the data distribution). The following hypotheses are used for the estimation of the sample size calculation: * Power (1 - β) = 80% * Two-sided significance level (α) = 5% * Expected inter-group difference = 0.6g * Standard deviation = 1.4g. Statistical analyses is performed with SAS® version 9.4 or higher (SAS institute, North Carolina, USA). Continuous variables are summarized as number of observations, mean, standard deviation, standard error, median, minimum and maximum (95% confidence interval will be provided if necessary). For categorical variables, subject counts and percentages will be provided. Analyses use 2-sided tests at the 5% significance level, except the normality tested at the threshold of 1% (Shapiro-Wilk test).
Study Type
OBSERVATIONAL
Enrollment
119
application of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment
application of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment
DOST
Svidník, Slovakia
efficacy of treatments
the efficacy of treatments is evaluated by corticosteroids consumption (weight of product and number of applications)
Time frame: from baseline to Day84
change in SCORing Atopic Dermatitis (SCORAD) measure
evaluation of SCORAD by the dermatologist in relation with the emollient consumption (weight of product and number of applications)
Time frame: from baseline to Day84
change in Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD) measure
evaluation of PO-SCORAD by the patient in relation with the emollient consumption (weight of product and number of applications)
Time frame: from baseline to Day84
change in LOCAL SCORing Atopic Dermatitis (LOCAL SCORAD) measure
evaluation of LOCAL SCORAD by the dermatologist in relation with the emollient consumption (weight of product and number of applications)
Time frame: from baseline to Day84
change in cutaneous discomfort
evaluation of skin sensation (itching, tingling, burning) by the patient on a 4-point scale (from absence to severe)
Time frame: from baseline to Day84
change in global efficacy
evaluation of global efficacy by the patient on a 4-point scale (from nil to excellent)
Time frame: from Day28 to Day84
change in global tolerance
evaluation of global tolerance of the treatment (emollient + corticosteroid) by the patient on a 4-point scale (from nil to excellent)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: from Day28 to Day84
change in Patient Benefit Index (PBI) measure
questionnaire filled in by the patient or the patient's parents (whether the statement applies to the situation or not, possible answers: not at all, somewhat, moderately, quite, very, does not apply to me)
Time frame: from baseline to Day84
change in the quality of life (patients aged 18 years or over)
questionnaire about the Atopic Burden Scale for Adults (ABS-A) with the following scale: never, rarely, sometimes, often, very often, constantly, not applicable. A higher score means a higher burden.
Time frame: from baseline to Day84
change in the quality of life (patients aged less than 18 years)
questionnaire about the Atopic Dermatitis Burden Scale for the Family (ABS-F) with the following scale: no, without hesitation; I don't know; maybe; yes, without hesitation; not applicable. A higher score means a higher burden.
Time frame: from baseline to Day84